Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 519 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ScottishPower help us shine a light on air pollution and cancer December 9, 2021 Embedding research integrity at the core of our science July 28, 2021 Berry Recipes August 14, 2020 Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours September 5, 2023 Load more HOT NEWS Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... EMA Recommends Extension of Indications for Durvalumab to Include Treatment of... Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... Jonas Brothers Visit Fan In Hospital Who Missed Their Concert Due...
